Literature DB >> 19371809

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Salvatore L Ruggiero1, Thomas B Dodson, Leon A Assael, Regina Landesberg, Robert E Marx, Bhoomi Mehrotra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19371809     DOI： 10.1016/j.joms.2009.01.009

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN： 0278-2391            Impact factor:   1.895


× No keyword cloud information.
  281 in total

1.  Experience with alendronate treatment for 7 years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Authors:  Jun Iwamoto; Mitsuyoshi Uzawa
Journal:  Clin Rheumatol       Date:  2014-11-01       Impact factor: 2.980

Review 2.  Efficacy of antiresorptive agents for preventing fractures in Japanese patients with an increased fracture risk: review of the literature.

Authors:  Jun Iwamoto; Yoshihiro Sato; Tsuyoshi Takeda; Hideo Matsumoto
Journal:  Drugs Aging       Date:  2012-03-01       Impact factor: 3.923

3.  Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.

Authors:  Johannes K-H Meier; Daniel Wolff; Steve Pavletic; Hildegard Greinix; Martin Gosau; Hartmut Bertz; Stefanie J Lee; Anita Lawitschka; Sharon Elad
Journal:  Clin Oral Investig       Date:  2010-09-22       Impact factor: 3.573

Review 4.  A systematic review of bisphosphonate osteonecrosis (BON) in cancer.

Authors:  Cesar Augusto Migliorati; Sook-Bin Woo; Ian Hewson; Andrei Barasch; Linda S Elting; Fred K L Spijkervet; Michael T Brennan
Journal:  Support Care Cancer       Date:  2010-04-22       Impact factor: 3.603

5.  RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem?

Authors:  Tim Van den Wyngaert; Kristien Wouters; Manon T Huizing; Jan B Vermorken
Journal:  Support Care Cancer       Date:  2011-01-04       Impact factor: 3.603

6.  Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.

Authors:  Matthew R Allen; Neal X Chen; Vincent H Gattone; Sharon M Moe
Journal:  Am J Nephrol       Date:  2013-11-22       Impact factor: 3.754

7.  Salivary proteomics in bisphosphonate-related osteonecrosis of the jaw.

Authors:  V Thumbigere-Math; B S Michalowicz; E P de Jong; T J Griffin; D L Basi; P J Hughes; M L Tsai; K K Swenson; L Rockwell; R Gopalakrishnan
Journal:  Oral Dis       Date:  2013-11-29       Impact factor: 3.511

8.  Spontaneous osteonecrosis of the jaws in the maxilla of mice on antiresorptive treatment: a novel ONJ mouse model.

Authors:  Rafael Scaf de Molon; Simon Cheong; Olga Bezouglaia; Sarah M Dry; Flavia Pirih; Joni Augusto Cirelli; Tara L Aghaloo; Sotirios Tetradis
Journal:  Bone       Date:  2014-08-02       Impact factor: 4.398

9.  Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process.

Authors:  Giordana Bettini; Stella Blandamura; Giorgia Saia; Alberto Bedogni
Journal:  BMJ Case Rep       Date:  2012-10-22

Review 10.  Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases.

Authors:  Sven Otto; Christoph Pautke; Sigurd Hafner; Ronny Hesse; Lea Franziska Reichardt; Gerson Mast; Michael Ehrenfeld; Carl-Peter Cornelius
Journal:  Craniomaxillofac Trauma Reconstr       Date:  2013-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.